Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ST-HT
- Development stage
- Phase 3
- Lead developer
- SSP
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ST-HT is a multi-ingredient oral combination medication developed by SSP Co., Ltd. (a subsidiary of Sanofi) for the symptomatic relief of the common cold. It is a fixed-dose combination containing ibuprofen (an analgesic and antipyretic), ambroxol hydrochloride and L-carbocisteine (mucolytics), isopropamide iodide (an anticholinergic to reduce nasal secretions), chlorpheniramine maleate (an antihistamine), dihydrocodeine phosphate (a cough suppressant), and dl-methylephedrine hydrochloride (a bronchodilator and decongestant). This comprehensive formulation is designed to target multiple cold symptoms simultaneously, including fever, sore throat, cough, phlegm, and runny nose. It was evaluated in Phase III clinical trials in Japan and is marketed as an over-the-counter (OTC) product under the brand name Estac EX Neo.
- Brand names
- Estac EX Neo
- Other names
- エスタックEXネオ
02
Targets
KEAP1 (Kelch-like ECH-associated protein 1)MUC2 (Mucin-2)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)AKT (RAC-alpha serine/threonine-protein kinase)CHRM3 (M3)HRH1 (Histamine H1 Receptor)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)KCNH2 (Voltage-gated potassium channel subfamily H member 2)DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)ADRA1 (Alpha-1 adrenergic receptor family)ADRA2 (Adrenergic alpha-2 receptor family)ADRB1 (β1)VMAT2 (Vesicular monoamine transporter 2)ADRA1A (α1A)ADRA1B (α1B)ADRA1D (α1D)ADRA2A (α2A)ADRA2B (α2B)ADRA2C (α2C)β-AR (Beta-adrenergic receptor family)
Beyond the preview
Go deeper on ST-HT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ST-HT.